[go: up one dir, main page]

WO2011084025A2 - Extrait d'hexane - Google Patents

Extrait d'hexane Download PDF

Info

Publication number
WO2011084025A2
WO2011084025A2 PCT/KR2011/000159 KR2011000159W WO2011084025A2 WO 2011084025 A2 WO2011084025 A2 WO 2011084025A2 KR 2011000159 W KR2011000159 W KR 2011000159W WO 2011084025 A2 WO2011084025 A2 WO 2011084025A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
weight
parts
insomnia
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/000159
Other languages
English (en)
Korean (ko)
Other versions
WO2011084025A3 (fr
Inventor
조원기
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011084025A2 publication Critical patent/WO2011084025A2/fr
Publication of WO2011084025A3 publication Critical patent/WO2011084025A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/289—Vladimiria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to a nucleic acid extract, and more particularly, to a nucleic acid extract and a composition comprising the same, which are effective in alleviating and / or improving insomnia due to excellent sleep prolonging effect and monoamine oxidase inhibitory effect.
  • Insomnia means difficulty sleeping, at least one month, or wakes up more than three times a week, even if you fall asleep, and causes sleep deprivation during the day.
  • Sleep disorder is a symptom frequently occurring in modern people due to various causes, breaking the rhythm of life and causing huge disruption to social activities. Insomnia is closely related to the social activities of modern people, with the expectation that social problems and occupational factors account for 153 ⁇ 4-203 ⁇ 4. According to a recent survey, 73.4% of Koreans have experienced insomnia (Korea Institute for Health and Social Affairs, March 2000) and about 8% of patients with sleep disorders needing treatment (Korea Sleep Society, August 2000). ). As a modern sedative for treating or preventing insomnia, barbiturate-based drugs were introduced as an effective medicine for anxiety treatment in the early 1900's, but the treatment index has a low stability problem. Not solving it. have.
  • benzodiazepine-based drugs such as chlordiazepoxide were developed and started to be used as sedatives, and many derivatives have been developed as sedatives. These drugs are comparatively safe and have an anti-anxiety effect that alleviates anxiety symptoms, but they are also used as anticonvulsants, sedative sleeping pills, and muscle relaxants. Problems remain to be resolved, such as motor disorders, movement disorders, withdrawal of convulsions, enhanced central nervous system suppression when used with alcohol or barbiturate, and rarely cause anxiety symptoms and hostility. It can also cause side effects, such as an ideal sedative (J. Clin. Psych i at. 42, 1981, MA Schuckit, Current therapeutic opt i ons in the management of anxiety, pp. 15-24).
  • Buspirone an azaspirodecanedione-based drug that has been developed since the 1970s, does not bind to the benzodiazepine receptor, unlike other antianxiety agents. Although it does not directly affect the high GABA (Y-aminobutyric acid) nervous system and acts on dopamine and serotonin receptors in the hippocampus, it is known to have fewer side effects such as dyskinesia than the existing benzodiazepines.
  • GABA Y-aminobutyric acid
  • the problem to be solved by the present invention is to provide a nucleic acid extract and a composition comprising the same that is effective for insomnia relief and / or improvement.
  • the present invention provides nucleic acid extracts of cedar, scented scent, benzoic, scented, and cedar complexes.
  • the Dragon Brain (Ryong ⁇ , B0ME0LUM) was published in the Korean Pharmacopoeia Herbal Medicine (WC) Standard Collection (2007) It is also called ice floe, Borneo 1, etc., and it is obtained by steam distillation of poly resin or stem and branches from the trunk of Dryobalanops aromatica Gaertner (Dr. incense and Dipterocarpaceae). It is a white crystal.
  • Benzoinum Styrax benzoin Dryander or Styrax tonkinensis Craib ex Hart. Resin obtained from (Styracaceae).
  • Cyperus Rhizome is contained in the Korean Pharmacopoeia (9th Amendment) and is also called Cyperi Rhizoma, which is the root of the root of Cyperus rotundus Linne (Cyperaceae). Will be removed.
  • Mok-hyang ( ⁇ , AUCKLANDIAE RADIX) is stored in the Korean herbal medicine (Herbal Medicine) standard collection, this drug is called Mokyang ( ⁇ ) Aucldandia lappa Decne. (Chrysanthemum Compositae) is the root.
  • cedar scented scent
  • benzoin hyangbuja
  • cedar may be collected from nature or purchased on the market.
  • ⁇ 15> Among the above mixtures are not limited to the cedar, scented scent, Benzoin, hyangbuja, and neck fragrance is not limited to this, 50 to 200 parts by weight, 50 to 200 parts by weight of benzoin, 50-200 parts by weight of fragrant scent against 100 parts by weight of the brain It may be a ratio of 50 to 200 parts by weight of neck, preferably 100 parts by weight of scented aroma, 100 parts by weight of benzoin, 100 parts by weight of fragrance and 100 parts by weight of cedar.
  • the nucleic acid extracts are camphor, camphor, alpha- copaene , beta- elemen ⁇ cyperene , beta- celinene , alpha- selenene , delta-cardinene, 9, 10-dehydroisotransporter pollen 8 , 9-dehydroiso ventolene, alpha-cyferon, benzylbenzoate, benzylcinnamate, and methyldihydroisofimarate.
  • the nucleic acid extract may be administered in a conventional manner, but preferably, by inhalation, the nucleic acid extract may have a rapid effect without the objection of the subject and avoid side effects.
  • the nucleic acid extract of the present invention may be formulated further including excipients, carriers, and / or diluents, and preferably pharmaceutically acceptable excipients, carriers and / or It can be formulated using a diluent or the like.
  • the composition of the present invention may be administered in a conventional formulation, and may be preferably formulated in a formulation such as an inhalant.
  • Preferred examples of the unit Brother lactose ( ⁇ ), and the preferable example of the support is dextran, and preferred examples of yae the diluent ethanol.
  • the present invention provides a composition for improving insomnia and / or alleviation comprising the nucleic acid extract of the present invention.
  • the improvement means that the symptoms of insomnia are better and the alleviation means that the symptoms of insomnia are prevented from becoming worse.
  • the nucleic acid extract is an active ingredient or active ingredient included in the composition.
  • the composition of the present invention is preferably a fragrance composition or a pharmaceutical composition.
  • the pharmaceutical composition may include a pharmaceutically acceptable carrier and the like, and the fragrance composition may be prepared by including a carrier and the like which are allowed in the preparation of the fragrance.
  • the fragrance is meant to include fragrances, fragrances, perfume oils and the like.
  • the pharmaceutical composition may be for the treatment and / or prophylaxis of insomnia, the treatment and / or prevention of insomnia may be by monoamine oxidase inhibition, may be due to insomnia improvement and / or alleviation.
  • the dose of the nucleic acid extract or composition of the present invention may be determined according to the route of administration, the dosage form, the purpose of use, and the degree of disease of the patient. For example, the dose of l ⁇ 2mg / kg / day based on the nucleic acid extract may be determined. Can be administered by inhalation through the respiratory system.
  • the present invention also provides a use for improving insomnia and / or alleviating insomnia, preferably for treating insomnia, and / or for preventing prophylaxis of cerebellar, scented, benzoate, scented, and cedar complex nucleic acid extracts.
  • the present invention provides a method for improving and / or alleviating insomnia, preferably for treating and / or preventing insomnia, comprising administering to a subject in need thereof a nucleic acid extract of cerebellar, scented, benzoate, scented, and cedar complex. To provide.
  • nucleic acid extract of the present invention The matters mentioned in the nucleic acid extract of the present invention, the use of improving the composition of insomnia and / or alleviating agent, and the method of improving the insomnia and / or alleviating the same function as the contrary.
  • the nucleic acid extract of the present invention may be prepared by a nucleic acid extraction method, specifically, selecting a medicine and determining a compounding ratio; Powdering the medicine and mixing the mixture according to a mixing ratio; Adding nucleic acid to the powder and extracting at 25 degrees Celsius; And removing the nucleic acid with a concentrator.
  • the nucleic acid extract of the present invention exhibits an effect of prolonging sleep and inhibiting monoamine oxidase, and does not show side effects such as dizziness, and is effective for improving insomnia and / or alleviating insomnia.
  • the solvent extract of the present invention and the composition comprising the same have an effect of extending sleep and inhibiting monoamine oxidase, and are effective in improving and / or alleviating insomnia.
  • FIG. 1 is a diagram illustrating a graph of chromatographic analysis of Experimental Example 1.
  • nucleic acid extracts were prepared in the same manner as in Example 1.
  • Example 1 Seven mice ⁇ Dae Bio Bio Co., Ltd. ⁇ were prepared as Example 1 administration group.
  • Example 1 The dosing group is placed in a cage in a special kennel with minimal external air. Sleep effect was measured by allowing the mice to spontaneously inhale the hexane extract aroma of Example 1 (a dose corresponding to 1.5 mg / kg / day of human standard). At this time, the inhalation time was 3 hours in the day, 3 hours in the afternoon, 6 hours in total, inhaled for 7 days. One hour after the last inhalation, 50 mg / kg of the sleeping drug pentotal sodium was dissolved in saline and intraperitoneally injected to observe how long the sleeping time was extended by the sleeping agent. Sleeping time was measured by comparing the time until the recovery of the clove reflected on the basis of the point of disappearing the righting reflex by touching the tip of the nose of the mouse.
  • the control group was administered in the same manner as in Example 1 except that the nucleic acid extract of Example 1 was not administered, and the positive control group was a sedative chlor promazine hydrochloride instead of the nucleic acid extract of Example 10. Except for oral administration of mg / kg was carried out in the same manner as in Example 1 administration group.
  • Comparative Example 1 administration group was carried out in the same manner as in Example 1 except that the nucleic acid extract of Comparative Example 1 was administered. All experimental results were statistically analyzed using the Origin (Version 7.0) program. When significance was recognized, the significance test was performed below p ⁇ 0.05 level using Student's -test. The results are shown in the table below. Sleep time in the table is the mean standard error, and the rate of increase is a percentage of the control time.
  • the comparative example 1 administration group was significantly (p ⁇ 0.05) extended by 8.8 minutes, but the example 1 administration group was significantly (p ⁇ 0.05) extended by 22.9 minutes.
  • the increase in the sleeping time is more than four times greater than that of the control group compared to the control group of the administration of Example 1 in comparison.
  • the solvent extract of the present invention can prolong sleep time without waking up, and is effective for improving insomnia and / or alleviating insomnia.
  • the sleep effect can be exhibited without side effects by a simple inhalation, regardless of methods such as oral administration and injection.
  • mice treated with Example 1 had side effects such as dizziness. Not observed.
  • Monoamine oxidase is an enzyme that catalyzes the oxidative deamine reaction of monoamines (serotonin, dopamine, epinephrine, norepinephrine, etc.) to remove amino groups from molecules to form aldehydes and ammonia. .
  • Serotonin the substrate for this enzyme, is a neurotransmitter related to sleep. Therefore, the effects of inhibiting monoamine oxidase, which degrades serotonin, may be effective in improving sleep disorders (Jouvet, M. Biogenic amines and the states of sleep: pharmacological and neurophus io 1 ogi ca 1 studies suggest a relationship between brain serotonin and sleep.See Science 163, 32-41 (1969)).
  • the enzyme source for measuring monoamine oxidase activity was prepared by the following method. That is, brain tissues were extracted from experimental animals (mouse; Dae Bio Biolink), and then washed once with a small amount of 0.32M cold sucrose solution. A 10% (w / v) homogenate was prepared from the above sucrose solution, followed by centrifugation at 1,000 ⁇ for 10 minutes to obtain a supernatant. The precipitate was washed twice with a small amount of sucrose, and then the supernatant and wash were combined and centrifuged at 12,000X for 20 minutes. The obtained pellet (mitochondrial fraction) was washed once with a sucrose solution and then used as an enzyme source. The above operation was carried out at 0 ⁇ 4 ° C.
  • control test further comprises the step of stopping the enzyme reaction by heating 103 ⁇ 4> (w / v) homogenate made of sucrose solution at 100 ° C for 5 minutes, after which no nucleic acid extract is added. Except for the same procedure as above.
  • the nucleic acid extract of the present invention exhibits the effect of inhibiting monoamine oxidase, thus exhibiting the effect of maintaining sleep, and consequently, it is effective in improving and / or alleviating insomnia.
  • it can be seen that it is possible to control the degree of insomnia improvement and / or alleviation effect by adjusting the dose because it can inhibit the enzyme activity in a dose-dependent manner. As a result, it is possible to control the improvement and / or alleviation of insomnia so that side effects from excessive sleep are not generated.
  • ⁇ 5i> The components and contents of the nucleic acid extract prepared in Example 1 were analyzed by GC-MS method.
  • GC-MS HP 6890 series; Hewlett-Packard
  • the column was measured using an HP capillary column (60.0 mx 250 ⁇ x 0.25 ⁇ ).
  • the gas used for the measurement is nitrogen and the measurement conditions are as follows.
  • the initial temperature is maintained at 40 ° C for 5 minutes, then increased by 5 ° C in 1 minute to 90 ° C and maintained at this temperature for 5 minutes, then increased by 5 ° C in 1 minute Raise it up to 110 ° C and hold at this temperature for 10 minutes, then raise it by 2 ° C in 1 minute, raise it to 230 ° C, hold it for 5 minutes at this temperature, and finally raise it to 300 ° C, The measurement was continued.
  • the chromatographic analysis result graph is shown in FIG. 1 and shows the retention time and content in the following table.
  • the X axis of FIG. 1 represents the retention time and the y axis represents the abundance. ⁇ 53> [Table 3]
  • the nucleic acid extract of the present invention is camphor, camphor, alpha-copaene, beta-elemen, cyperene, beta-celinene, alpha-selenene, delta-cardinene, 9, 10-dehydroyi. It can be seen that it includes a communicator pollen, 8,9-dehydroisolinker pollen, alpha-cyferon, benzylbenzoate, benzylcinnamate, and methyldihydroisopimarate.
  • the present invention provides nucleic acid extracts of cedar, scented scent, benzoic, scented, and cedar complexes.
  • the solvent extract of the present invention exhibits the effect of prolonging sleep and producing monoamine oxidase inhibitors, and is effective in improving insomnia and / or alleviating insomnia and thus has industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a pour objet des compositions pour le traitement et le soulagement de l'insomnie qui comprennent des extraits d'hexane tels que le bornéol, le stacte, la benzoïne, l'herbe de coco, et un mélange de parfums boisés. Les extraits d'hexane prolongent le sommeil, manifestent une activité dépressive des monoamine oxydases, et sont efficaces dans le traitement et/ou le soulagement de l'insomnie.
PCT/KR2011/000159 2010-01-11 2011-01-11 Extrait d'hexane Ceased WO2011084025A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100002100A KR101016906B1 (ko) 2010-01-11 2010-01-11 헥산추출물
KR10-2010-0002100 2010-01-11

Publications (2)

Publication Number Publication Date
WO2011084025A2 true WO2011084025A2 (fr) 2011-07-14
WO2011084025A3 WO2011084025A3 (fr) 2011-11-10

Family

ID=43777824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000159 Ceased WO2011084025A2 (fr) 2010-01-11 2011-01-11 Extrait d'hexane

Country Status (2)

Country Link
KR (1) KR101016906B1 (fr)
WO (1) WO2011084025A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104771437A (zh) * 2015-04-22 2015-07-15 臧海阳 一种治疗心脾不足型失眠的中药组合物
KR20180058627A (ko) * 2016-11-24 2018-06-01 (주)아모레퍼시픽 둥근정향나무꽃의 향취를 재현한 향료 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101809008B1 (ko) 2016-01-29 2017-12-14 동아대학교 산학협력단 수면 장애 개선용 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000073624A (ko) * 1999-05-12 2000-12-05 정석용 한약 청향제의 제조 방법
KR19990083924A (ko) * 1999-08-27 1999-12-06 한상준 한방향기주머니.한방약베개
KR100523452B1 (ko) * 2002-02-28 2005-10-24 이동웅 한약재 향기성분을 함유하는 불면 및 경련의 치료 및예방용 약제학적 조성물
KR20090112268A (ko) * 2008-04-24 2009-10-28 동국대학교 산학협력단 베타-아밀로이드로 유발된 뇌세포 손상의 치료 및 예방용약제학적 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104771437A (zh) * 2015-04-22 2015-07-15 臧海阳 一种治疗心脾不足型失眠的中药组合物
KR20180058627A (ko) * 2016-11-24 2018-06-01 (주)아모레퍼시픽 둥근정향나무꽃의 향취를 재현한 향료 조성물
KR102213993B1 (ko) 2016-11-24 2021-02-09 (주)아모레퍼시픽 둥근정향나무꽃의 향취를 재현한 향료 조성물

Also Published As

Publication number Publication date
KR101016906B1 (ko) 2011-02-22
WO2011084025A3 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
CN107233412B (zh) 一种促进睡眠的复方精油组合物及其制备方法和用途
AU2021201949A1 (en) Device with compositions for delivery to the lungs, the oral mucosa and the brain
Stinson et al. Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies
BR122021018502B1 (pt) Formulação de canabinoide líquida
JP5266254B2 (ja) 選択的セロトニン再取り込み阻害組成物およびその方法
US20180193304A1 (en) Phytoterpenoid facilitation of therapeutic onset and efficacy of sublingual cannabinoid administration
CN105285986A (zh) 含有栗子皮提取物的健康食品或药学组合物
KR101016906B1 (ko) 헥산추출물
CN104628657A (zh) 一类治疗缺血性脑损伤的化合物及其用途
CN114652784B (zh) 具有镇静催眠和改善记忆功效的复方精油及其制备方法
CN101167889A (zh) 一种治疗昏厥、风湿性关节炎的中药
CN104116968A (zh) 一种具有镇静安神治疗失眠的中药制剂
CN1977890B (zh) 一种中药组合物及其用途
KR100523452B1 (ko) 한약재 향기성분을 함유하는 불면 및 경련의 치료 및예방용 약제학적 조성물
KR20110019977A (ko) 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물
CN106266959A (zh) 一种治疗跖疣的复方洗剂
CN104524519A (zh) 一种感冒初期患者适用的特种纸手帕
CN105726779A (zh) 一种用于戒毒的中药组合物及其制备方法
CN110025666A (zh) 一种降真香助眠膏及其在制备治疗失眠药物中的应用
CN102885539B (zh) 一种缓解小儿夜惊的药枕
CN110279748A (zh) 一种厚朴精油的应用
CN100398138C (zh) 一种抗抑郁和治疗低体温症的中药
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
Mathew An Unexplored Under-recognized
CN104586691A (zh) 一种芳香精油喷剂及其在特种纸手帕制备中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731963

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11731963

Country of ref document: EP

Kind code of ref document: A2